Covid-19

#Clinical trials #Covid-19 #GlobalData

UK falls behind other countries in clinical trial activity 

While trial activity has since recovered to pre-Covid-19 pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData.  Hillman explained that the UK commenced 18% fewer commercial trials during the first three quarters of 2021 than… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug discovery #Pharmaceuticals

Newly launched antiviral nasal spray reduced Covid in ICU by 80%  

Amcyte Pharma has launched Nasitrol nasal spray for sinus irrigation in the US. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced Covid transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of Covid-19.   What… Read More

#News

#Antibodies #Biotherapeutics #Covid-19 #Data #Funding #Immunology / Virology & Vaccines

Twist Bioscience spins out Covid antibodies into Revelar Biotherapeutics

Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.   In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More

#Covid-19 #News

#Collaboration #Covid-19 #Research

This week in drug discovery (15-19 November) 

News round-up by DDW’s Megan Thomas for 15-19 November  As the world emerges from the Covid-19 pandemic, DDW’s Megan Thomas has rounded up five stories which show how the drug discovery industry has used what it has learnt over the last two years to innovate for the… Read More

#News #Trending News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines

T-cell vaccines may offer “significant benefits” over current Covid-19 vaccines 

Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.  The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high… Read More

#Covid-19 #News

#Covid-19 #Healthcare #Life sciences #Lipids

Evonik eyes Canadian opportunities in Covid-19 fight 

Evonik met with a delegation of representatives from Canada at its site in Darmstadt to discuss competencies in lipid nanoparticles at Evonik’s Vancouver laboratories and evaluate future collaboration opportunities.   Evonik has sites in seven locations in Canada including its Vancouver Laboratories in British Columbia for lipid-based parenteral drug delivery which… Read More

#News #Trending News #Trends & Analysis

#Biology #Collaboration #Covid-19 #Research

CN Bio and iiCON announce Covid-19 research collaboration

CN Bio has entered a research collaboration with the Infection Innovation Consortium (iiCON) to validate the next generation of Covid-19 research tools.  iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products. Led by the Liverpool School of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Measles

Global progress against measles threatened amidst Covid-19 pandemic  

While reported measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a new report from the World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC).   During 2020, more than 22… Read More

#News #Trending News #Trends & Analysis

#Antivirals #Covid-19 #Research

How will this anti-viral nasal spray protect against Covid-19? 

Birmingham Biotech and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against Covid-19. The formulation was engineered by Professor Liam Grover, from the university’s Healthcare Technologies Institute, and a team of researchers who also collaborated on its testing.  Covid-19… Read More

#Covid-19 #News

#Antivirals #Biotherapeutics #Covid-19 #Immunology / Virology & Vaccines

Beximco Pharma introduces an oral antiviral drug for Covid-19 treatment 

Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh.   Molnupiravir is world’s first oral product to treat symptomatic Covid-19,… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

#Antivirals #Biologics #Biopharmaceuticals #Collaboration #Covid-19 #Laboratory data

This week in drug discovery (1-5 November) 

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent… Read More

#News #Trending News

#Biotherapeutics #Clinical trial #Covid-19 #FDA

UK becomes first country to approve a Covid-19 antiviral pill 

The MHRA has authorised Merck and Ridgeback Biotherapeutics’ molnupiravir pill for the treatment of at-risk Covid-19 patients, following positive clinical trial results. Molnupiravir is the first oral antiviral medicine authorised for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk… Read More

#News

#Biology #Covid-19 #Research

SARS-CoV-2 virus does not infect blood vessels, study shows 

University of Queensland (UQ) researchers have found that the SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots in Covid-19 patients. They found that the cardiovascular complications of Covid-19 are triggered by inflammation caused by infected airway cells.  Dr Emma Gordon and… Read More

#News #Trending News